REV102

REV102 is an orally available, small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), being developed for the treatment of hypophosphatasia (HPP). HPP is a rare genetic disorder characterized by impaired mineralization of bones and teeth due to mutations in the ALPL gene. By inhibiting ENPP1, REV102 reduces levels of inorganic pyrophosphate (PPi), aiming to restore the balance between PPi and phosphate necessary for proper bone mineralization. The drug is currently in preclinical development and is being advanced through a joint venture between Rallybio and Recursion Pharmaceuticals[1][2][3].